Viridian Therapeutics

121 articles with Viridian Therapeutics

• Viridian Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Preferred Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

  9/23/2021

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, today announced the closing of an underwritten public offering of 7,344,543 shares of common stock,

• Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock and Preferred Stock - Sep 21, 2021

  9/21/2021

  Viridian Therapeutics, Inc., a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by 's therapies, today announced the pricing of an underwritten public offering with gross proceeds of approximately $85.0 million.

• Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

  9/20/2021

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that it has commenced an underwritten public offering of shares of its common stock and series B preferred stock (the “Series B Preferred”).

• Viridian Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Updates

  8/11/2021

  Viridian Therapeutics, Inc. today announced financial results for the second quarter ended June 30, 2021, and provided corporate updates.

• Viridian Therapeutics to Participate in the Wedbush PacGrow Healthcare Virtual Conference

  8/5/2021

  Viridian Therapeutics, Inc. today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer, and Barrett Katz, M.D., M.B.A., Chief Medical Officer of Viridian, will participate in a panel presentation at the Wedbush PacGrow Healthcare Virtual Conference, which is scheduled to take place on August 10-11, 2021.

• 

  BioSpace Movers & Shakers, July 30, 2021

  7/30/2021

  Biopharma and life science companies strengthen their leadership teams and boards with these Movers & Shakers.

• Viridian Therapeutics Appoints Kristian Humer as Chief Financial Officer and Chief Business Officer

  7/26/2021

  Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced the appointment of Kristian Humer as its new Chief Financial Officer and Chief Business Officer.

• Viridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Directors and as Chair of the Audit Committee

  7/15/2021

  Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced the appointment of Jennifer Moses, CPA to the Company’s Board of Directors and as Chair of the Audit Committee.

• Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - July 14, 2021

  7/14/2021

  Viridian Therapeutics, Inc., a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by current therapies, announced that a majority of the independent directors serving on the Company’s Board of Directors approved the grant of an option to purchase 180,000 shares of the Company’s common stock to a new employee.

• Viridian Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference

  7/7/2021

  Viridian Therapeutics, Inc. today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will present a company overview at the virtual Ladenburg Thalmann 2021 Healthcare Conference taking place July 13 – 14, 2021.

• Viridian Therapeutics to Participate in the JMP Securities Life Sciences Conference

  6/10/2021

  Viridian Therapeutics, Inc. (Nasdaq: VRDN), today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will participate in a fireside chat at the virtual JMP Securities Life Sciences Conference

• Viridian Therapeutics to Participate in Upcoming Investor Conferences - May 14, 2021

  5/14/2021

  Viridian Therapeutics, Inc. announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will present a company overview at the virtual Oppenheimer Rare & Orphan Disease Summit and participate in a fireside chat at the Jefferies Virtual Healthcare Conference.

• Viridian Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates

  5/6/2021

  Viridian Therapeutics, Inc., a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by current therapies, announced financial results for the first quarter of 2021 and provided corporate updates.

• Viridian Therapeutics Reports 2020 Financial Results and Provides Corporate Updates

  3/25/2021

  Progressed lead programs VRDN-001 and VRDN-002 towards clinical trials in Thyroid Eye Disease (TED); both IND filings expected by the end of 2021 Completed integration and name change to Viridian Therapeutics following October 2020 merger and concurrent financing

• Viridian Therapeutics To Host Conference Call Discussing Fourth Quarter And Full Year 2020 Results And Corporate Update

  3/9/2021

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that it will host a conference call and webcast on Thursday, March 25, 2021 at 4:30 p.m. ET to discuss a corporate update and results for the fourth quarter and full year 2020.

• Viridian Therapeutics to Present at Three Upcoming Investor Conferences

  2/22/2021

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a development-stage biopharmaceutical company, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will present a company overview at the following upcoming investor conferences: Event: SVB Leerink 10 TH Annual Global Healthcare Conference 2021 (Virtual) Date:  Wednesday, February 24 TH Presentation Time: 1:00 p.m. EST     

• 

  BioSpace Movers & Shakers, Jan. 22

  1/22/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team

  1/19/2021

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“Viridian”).

• miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease

  12/17/2020

  Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology miRagen expects to file an Investigational New Drug (IND) application for VRDN-002, including half-life extension, by the end of 2021

• miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

  11/10/2020

  Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED) Private placement financing proceeds of approximately $91 million positions miRagen to potentially advance multiple compounds through Phase 2 proof of concept studies in TED and expand its orphan disease pipeline